BR112015028964A2 - composição de suspensão, e, método para tratar uma doença ou um distúrbio pulmonar - Google Patents

composição de suspensão, e, método para tratar uma doença ou um distúrbio pulmonar

Info

Publication number
BR112015028964A2
BR112015028964A2 BR112015028964A BR112015028964A BR112015028964A2 BR 112015028964 A2 BR112015028964 A2 BR 112015028964A2 BR 112015028964 A BR112015028964 A BR 112015028964A BR 112015028964 A BR112015028964 A BR 112015028964A BR 112015028964 A2 BR112015028964 A2 BR 112015028964A2
Authority
BR
Brazil
Prior art keywords
treating
systems
disorder
pulmonary disease
suspension composition
Prior art date
Application number
BR112015028964A
Other languages
English (en)
Inventor
Reisner Colin
Lechuga-Ballesteros David
Fitzgerald Darken Patrick
Kumar Dwivedi Sarvajna
B Joshi Vidya
Original Assignee
Pearl Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pearl Therapeutics Inc filed Critical Pearl Therapeutics Inc
Publication of BR112015028964A2 publication Critical patent/BR112015028964A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

1 / 1 resumo “composiã‡ãƒo de suspensãƒo, e, mã‰todo para tratar uma doenã‡a ou um distãšrbio pulmonar” sã£o descritos composiã§ãµes farmacãªuticas, sistemas e mã©todos adequados para ministraã§ã£o por via respiratã³ria de uma combinaã§ã£o fixa de agentes ativos lama, laba e ics. as composiã§ãµes farmacãªuticas descritas aqui podem ser formuladas para ministraã§ã£o por via respiratã³ria por meio de um inalador dosimetrado (mdi). tambã©m descritos aqui sã£o sistemas de mdi para ministraã§ã£o de uma combinaã§ã£o fixa de agentes ativos lama, laba e ics, assim como mã©todos para preparar e usar as composiã§ãµes e sistemas descritos aqui.
BR112015028964A 2013-05-22 2014-05-22 composição de suspensão, e, método para tratar uma doença ou um distúrbio pulmonar BR112015028964A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361826424P 2013-05-22 2013-05-22
PCT/US2014/039234 WO2014190204A1 (en) 2013-05-22 2014-05-22 Compositions, methods & systems for respiratory delivery of three or more active agents

Publications (1)

Publication Number Publication Date
BR112015028964A2 true BR112015028964A2 (pt) 2017-07-25

Family

ID=50942948

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015028964A BR112015028964A2 (pt) 2013-05-22 2014-05-22 composição de suspensão, e, método para tratar uma doença ou um distúrbio pulmonar

Country Status (20)

Country Link
US (1) US20150150787A1 (pt)
EP (1) EP2999460A1 (pt)
JP (1) JP2016519160A (pt)
KR (1) KR20160013134A (pt)
CN (1) CN105392471A (pt)
AU (1) AU2014268482A1 (pt)
BR (1) BR112015028964A2 (pt)
CA (1) CA2912927A1 (pt)
CL (1) CL2015003422A1 (pt)
CR (1) CR20150645A (pt)
DO (1) DOP2015000284A (pt)
HK (2) HK1221653A1 (pt)
MX (1) MX2015016058A (pt)
NI (1) NI201500163A (pt)
PE (1) PE20160155A1 (pt)
PH (1) PH12015502593A1 (pt)
RU (1) RU2015154720A (pt)
SG (1) SG11201509543YA (pt)
WO (1) WO2014190204A1 (pt)
ZA (1) ZA201509016B (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3111926T (pt) 2009-05-29 2020-02-28 Pearl Therapeutics Inc Composições, métodos e sistemas para entrega respiratória de dois ou mais agentes ativos
JP5925342B2 (ja) * 2012-03-09 2016-05-25 ファイザー・インク 髄膜炎菌（Ｎｅｉｓｓｅｒｉａｍｅｎｉｎｇｉｔｉｄｉｓ）組成物およびその方法
MX2016006376A (es) * 2013-11-22 2016-10-28 Teva Branded Pharmaceutical Products R&D Inc Un medicamento inhalable.
DK3191081T3 (da) 2014-09-09 2020-06-15 Vectura Ltd Formulering, som omfatter glycopyrrolat, fremgangsmåde og indretning
WO2017108917A1 (en) * 2015-12-22 2017-06-29 Astrazeneca Ab Pharmaceutical compositions for use in the treatment of chronic obstructive pulmonary disease
US10098837B2 (en) * 2016-07-28 2018-10-16 Chiesi Farmaceutici S.P.A. Combination therapy for COPD
WO2019142214A1 (en) 2018-01-19 2019-07-25 Cipla Limited Pharmaceutical composition comprising tiotropium for inhalation
WO2020123057A2 (en) * 2018-10-31 2020-06-18 Repurposed Therapeutics, Inc. Dba Defender Treatment of exposure to chlorine gas with scopolamine
CN112137957B (zh) * 2019-06-26 2022-07-29 长风药业股份有限公司 一种药用吸入气雾剂及其制备方法
CN111349036B (zh) * 2020-03-13 2022-03-08 安徽恒星制药有限公司 一种格隆溴铵的替代物及其制备方法和医药用途
CN111467498A (zh) * 2020-05-14 2020-07-31 王兆霖 药物组合物制剂
CN111617138A (zh) * 2020-07-07 2020-09-04 上海凯宝药业股份有限公司 痰热清在制备慢性阻塞性肺病急性加重治疗药物中的应用
FI4197528T3 (fi) * 2021-07-09 2024-05-24 Astrazeneca Pharmaceuticals Lp Koostumuksia, menetelmiä ja järjestelmiä aerosolilääkkeen antamiseen
WO2023119093A1 (en) * 2021-12-20 2023-06-29 Astrazeneca Ab Compositions, methods and systems for aerosol drug delivery

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2956062A (en) 1959-02-26 1960-10-11 Robins Co Inc A H Esters of amino alcohols
US3994974A (en) 1972-02-05 1976-11-30 Yamanouchi Pharmaceutical Co., Ltd. α-Aminomethylbenzyl alcohol derivatives
SE378109B (pt) 1972-05-19 1975-08-18 Bofors Ab
DE3260474D1 (en) 1981-02-02 1984-09-06 Schering Corp Aromatic heterocyclic esters of steroids, their preparation and pharmaceutical compositions containing them
US5707634A (en) 1988-10-05 1998-01-13 Pharmacia & Upjohn Company Finely divided solid crystalline powders via precipitation into an anti-solvent
GB8903593D0 (en) 1989-02-16 1989-04-05 Pafra Ltd Storage of materials
SE9302777D0 (sv) 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
AU659645B2 (en) 1991-06-26 1995-05-25 Inhale Therapeutic Systems Storage of materials
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
GB9313642D0 (en) 1993-07-01 1993-08-18 Glaxo Group Ltd Method and apparatus for the formation of particles
SE9404080L (sv) 1993-12-28 1995-06-29 Ciba Geigy Ag Förfarande för framställning av en optiskt ren enantiomer av formoterol
US5837699A (en) 1994-01-27 1998-11-17 Schering Corporation Use of mometasone furoate for treating upper airway passage diseases
GB9413202D0 (en) 1994-06-30 1994-08-24 Univ Bradford Method and apparatus for the formation of particles
DE4440337A1 (de) 1994-11-11 1996-05-15 Dds Drug Delivery Services Ges Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit
CA2218074C (en) 1995-04-14 2002-10-08 Mohammed Eljamal Powdered pharmaceutical formulations having improved dispersibility
US6258341B1 (en) 1995-04-14 2001-07-10 Inhale Therapeutic Systems, Inc. Stable glassy state powder formulations
US6309671B1 (en) 1995-04-14 2001-10-30 Inhale Therapeutic Systems Stable glassy state powder formulations
US5833891A (en) 1996-10-09 1998-11-10 The University Of Kansas Methods for a particle precipitation and coating using near-critical and supercritical antisolvents
US5886200A (en) 1996-07-01 1999-03-23 Schering Corporation Process for the preparation of 17-esters of 9 α, 21-dihalo-pregnane-11 β, 17 α-diol-20-ones
US6040344A (en) 1996-11-11 2000-03-21 Sepracor Inc. Formoterol process
US6010935A (en) 1997-08-21 2000-01-04 Micron Technology, Inc. Self aligned contacts
US6309623B1 (en) 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
NZ500555A (en) 1999-08-02 2000-11-24 Hovione Int Ltd Process for the preparation of mometasone furoate
DK1666028T3 (da) 1999-10-29 2010-06-21 Novartis Ag Tørre pulversammensætninger med forbedret dispersitet
JP2007500234A (ja) 2003-05-28 2007-01-11 ネクター セラピューティクス 水に不溶な活性剤を含む医薬的成形
EP1904219A4 (en) 2005-07-15 2011-07-27 Map Pharmaceuticals Inc METHOD FOR FORMING PARTICLES
PT3111926T (pt) * 2009-05-29 2020-02-28 Pearl Therapeutics Inc Composições, métodos e sistemas para entrega respiratória de dois ou mais agentes ativos
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
KR20140012989A (ko) * 2011-02-17 2014-02-04 시플라 리미티드 글리코피롤레이트 및 베타2-효능제의 조합
CN103687483A (zh) * 2011-05-17 2014-03-26 珍珠治疗公司 用于呼吸递送两种或多种活性剂的组合物、方法和系统

Also Published As

Publication number Publication date
KR20160013134A (ko) 2016-02-03
AU2014268482A1 (en) 2016-01-07
CN105392471A (zh) 2016-03-09
CL2015003422A1 (es) 2016-09-02
US20150150787A1 (en) 2015-06-04
CA2912927A1 (en) 2014-11-27
HK1221654A1 (zh) 2017-06-09
DOP2015000284A (es) 2016-04-29
EP2999460A1 (en) 2016-03-30
HK1221653A1 (zh) 2017-06-09
WO2014190204A1 (en) 2014-11-27
PH12015502593A1 (en) 2016-02-29
NI201500163A (es) 2016-01-06
CR20150645A (es) 2016-02-10
ZA201509016B (en) 2018-07-25
PE20160155A1 (es) 2016-04-01
RU2015154720A (ru) 2017-06-27
MX2015016058A (es) 2016-12-20
JP2016519160A (ja) 2016-06-30
SG11201509543YA (en) 2015-12-30

Similar Documents

Publication Publication Date Title
BR112015028964A2 (pt) composição de suspensão, e, método para tratar uma doença ou um distúrbio pulmonar
CY1122807T1 (el) Συνθεσεις, μεθοδοι και συστηματα για τη χορηγηση δυο ή περισσοτερων δραστικων παραγοντων δια της αναπνευστικης οδου
PH12018500088A1 (en) Substituted tricyclics and method of use
IN2014DN09326A (pt)
CO6280490A2 (es) 4-(4-ciano-2-tioaril)dihidropirimidinonas y su uso
BR112017020039A2 (pt) composição farmacêutica, kit, método, processo para preparar uma composição e solução farmacêutica
CL2008001593A1 (es) Compuestos derivados de heterociclos, antagonistas para el ccr2; y uso de los compuestos para tratar afecciones o enfermedades del tracto respiratorio, como enfermedad pulmonar obstructiva cronica y asma.
EA201400591A1 (ru) Ингалятор
WO2013021199A3 (en) Eutectic mixture for pulmonary administration
WO2012047674A3 (en) Methods and compositions for disease treatment using inhalation
MX368903B (es) Compuestos terapéuticos y sus usos en el tratamiento de enfermedades proliferativas.
MX2013013440A (es) Composiciones, metodos y sistemas para suministro respiratorio de dos o mas agentes activos.
EA201591269A1 (ru) Способы лечения аутоиммунных, респираторных и воспалительных расстройств ингаляцией n-оксида рофлумиласта
BR112013001753A2 (pt) método para preparar uma composição d einter-alfa-inibidor (iaip) eriquecida de plasma, solução aquosa de iaip, e, método para tratar uma doença ou distúrbio associado com disfunção de iaip e associado com atividadede protease de serina no plasma aumentada.
EA201590030A1 (ru) Ингаляторы сухого порошка, содержащие носитель, отличный от лактозы, и третий компонент
ITMI20060158U1 (it) Apparecchiatura per la somministrazione di ossigeno o di aria addizionata da ossigeno,per terapie respiratorie.
BR112017023351A2 (pt) composições multidrogas de matriz frágil
EA201590019A1 (ru) Ингаляторы сухого порошка, содержащие носитель, отличный от лактозы
BR112014005538A2 (pt) composições aquosas compreendendo arbecacina
EA201591415A1 (ru) Фармацевтические композиции, включающие многокомпонентные кристаллические частицы, подходящие для применения в ингаляционной терапии
UA115989C2 (uk) Фармацевтична композиція для інгалятора сухого порошку, що містить антагоністи мускаринових рецепторів тривалої дії
BR112017014861A2 (pt) ?combinação e composição farmacêuticas, inalador de pó seco, uso de uma combinação farmacêutica, e, método para tratamento de um distúrbio pulmonar?
BR112015030341A2 (pt) formulações de nanoparticulado e processo para prepará-las, composição farmacêutica e uso de composto ou seu sal farmaceuticamente aceitável e estabilizante de superfície
NZ744942A (en) Compositions and methods for treating nasal and paranasal mucosa diseases with nicotinic acetylcholine receptor agonists
MY189372A (en) Indole derivatives

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2465 DE 03-04-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B350 Update of information on the portal [chapter 15.35 patent gazette]